H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results
On May 27, H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Tourmaline Bio, Inc. (NASDAQ:TRML) while keeping the price target at $50.
Tourmaline Bio Inc. (TRML)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Walleye Capital Will England | 0 | $0 | 0% | |
| 2. | RA Capital Management Peter Kolchinsky | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% | ||
| 4. | Citadel Investment Group Ken Griffin | 0 | $0 | 0% | |
| 5. | Millennium Management Israel Englander | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.85 | 1,779 | $26,418.15 | 7,000 | 2024-08-21 | Filing | |
| $13.79 | 5,221 | $71,997.59 | 5,221 | 2024-08-16 | Filing | |
| $32.50 | 100,000 | $3,250,000.00 | 448,431 | 2024-01-29 | Filing | |
| $16.99 | 4,000 | $67,960.00 | 729,735 | 2023-11-17 | Filing | |
| $17.31 | 1,000 | $17,310.00 | 83,782 | 2023-11-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.49 | 12,942 | $32,243.70 | 3,771,392 | 2023-06-14 | Filing | |
| $2.56 | 14,208 | $36,338.38 | 3,784,334 | 2023-06-13 | Filing | |
| $2.59 | 16,870 | $43,725.35 | 3,798,542 | 2023-06-12 | Filing | |
| $2.46 | 25,419 | $62,637.50 | 3,815,412 | 2023-06-09 | Filing | |
| $2.48 | 40,642 | $100,771.84 | 3,840,831 | 2023-06-08 | Filing |
Institutional Investors' Holdings
News See All
BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML)
The firm believes that the market’s negative reaction to Phase II data for the company’s drug, Paci, was excessive.